AMPH at a glance
Amphastar Pharmaceuticals, Inc. (AMPH, SEC CIK 1297184) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.9 million (down 1.7% from FY2024) and net income of $98.1 million. Diluted EPS was $2.03.
- As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Amphastar Pharmaceuticals, Inc. (AMPH) shares worth $415.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by PETERS WILLIAM J on November 16, 2026 of 11,000 shares at $29.99 per share.
- In the last 90 days, AMPH insiders reported 0 open-market purchases ($0) and 6 open-market sales ($1.6M) on Form 4, a net sale of $1.6M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $719.9M
- −1.7% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$1.6M
- 13F holders
- 28 funds
- $415.4M · −3 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 revenue $207.6M, up from $191.8M YoY, driven by BAQSIMI, Primatene MIST, and ipratropium bromide
- Gross profit $99.6M, margin 48.0% vs 51.4% YoY
- Best performer: BAQSIMI revenue $58.8M, up $5.2M; worst: glucagon $8.6M, down $5.0M, or 37%
- Nine-month operating cash flow $142.5M vs $123.3M; $100.0M BAQSIMI milestone payment and $75.1M treasury-stock purchases
- Outlook: glucagon sales expected to decline; IMS remediation may slow production and increase manufacturing expenses
Risk Factors
- IMS FDA warning letter, July 2, 2026, cited cGMP violations and triggered remediation efforts
- IMS product-release backlog approximately $12.5 million as of September 30, 2026
- IMS voluntarily suspended one product’s manufacture to prioritize products at shortage risk
- Insider-pledged shares expose stock price to forced-sale risk across 5.7 million pledged shares
- Credit lines totaled up to $57.0 million, including UBS’s unilateral call rights and lender acceleration rights
AI summary of the AMPH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for the three months ended September 30, 2026
- Investor focus: revenue, profitability, product performance and outlook in the referenced earnings release
Item EX-99.1: Item EX-99.1
- Q3 net revenues $207.6M, up 8%, led by BAQSIMI $58.8M and Primatene MIST $31.5M
- GAAP net income $37.8M, or $0.87 diluted EPS, versus $17.4M and $0.37 in Q3 2025
Item 2.02: Results of Operations and Financial Condition
- Amphastar reported financial results for the three months ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the quarter’s detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 revenue $183.9M, up 5%; gross margin improved to 50.8% from 49.6%, supported by higher-margin launches
- GAAP net income $30.3M, down from $31.0M; diluted EPS increased to $0.67 from $0.64 on fewer shares
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Board expanded from 10 to 11 directors with Anthony Pierce appointed as Class III director through 2028 annual meeting
- Pierce deemed Nasdaq-independent, with no related-party transactions or selection arrangements disclosed
AI summaries of AMPH 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AMPH
Don't miss the next AMPH filing
- Alerts as it files. A push when AMPH files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AMPH, by share count.
- Ask anything. An AI agent that reads every AMPH filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| PETERS WILLIAM J | Sell | Nov 16, 2026 | 11,000 | $29.99 |
| PETERS WILLIAM J | M | Nov 16, 2026 | 11,000 | - |
| PETERS WILLIAM J | M | Nov 16, 2026 | 11,000 | $17.99 |
| PETERS WILLIAM J | M | Nov 5, 2026 | 11,000 | $17.99 |
| PETERS WILLIAM J | M | Nov 5, 2026 | 11,000 | - |
| PETERS WILLIAM J | Sell | Nov 5, 2026 | 12,631 | $28.99 |
| PETERS WILLIAM J | M | Nov 4, 2026 | 16,000 | - |
| PETERS WILLIAM J | Sell | Nov 4, 2026 | 16,000 | $28.03 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $732.0M | $719.9M |
| Gross Profit | - | $373.9M | $356.1M |
| Operating Income | - | $205.4M | $140.4M |
| Net Income | - | $159.5M | $98.1M |
| Gross Margin | - | 51.1% | 49.5% |
| Op. Margin | - | 28.1% | 19.5% |
| Net Margin | - | 21.8% | 13.6% |
| Balance Sheet | |||
| Total Assets | $1.5B | $1.6B | $1.6B |
| Equity | $639.4M | $732.3M | $788.8M |
| ROE | - | 21.8% | 12.4% |
| Per Share | |||
| EPS | - | $3.06 | $2.03 |
| Cash Flow | |||
| Operating CF | - | $213.4M | $156.1M |
| CapEx | - | $41.0M | $34.9M |
Source: XBRL data in Amphastar Pharmaceuticals, Inc. (AMPH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AMPH share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 28 | $415.4M |
| Q2 2026 | 31 | $319.8M |
| Q1 2026 | 30 | $316.3M |
| Q4 2025 | 28 | $438.5M |
| Q3 2025 | 29 | $451.5M |
| Q2 2025 | 28 | $388.7M |
| Q1 2025 | 27 | $288.5M |
| Q4 2024 | 24 | $315.4M |
- D.E. Shaw & Co+258.1K (+29%)
- Citadel Advisors LLC+115.8K (+713%)
- Goldman Sachs Group+89.8K (+18%)
- Dimensional Fund Advisors+77.9K (+3%)
- Bank of America Corp+60.4K (+44%)
- Vanguard Capital Management LLC−242.6K (-16%)
- BlackRock−106.2K (-2%)
- AQR Capital Management−43.5K (-21%)
- Millennium Management−22.8K (-72%)
- Wells Fargo & Co−17.6K (-32%)
- FMR LLC (Fidelity)−29.0K
- Franklin Resources−25.0K
- Allstate−11.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 225 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AMPH filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 6, 2026 | - | - | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 4 | Sep 23, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 3, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| SC 13G | Jul 14, 2026 | - | - | |
| 4 | Jul 13, 2026 | - | - | - |
| 8-K | Jul 13, 2026 | - | Analysis | - |
| 8-K | Jul 8, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AMPH SEC filings: frequently asked questions
Are AMPH insiders buying or selling?
In the last 90 days, Amphastar Pharmaceuticals, Inc. (AMPH) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $1.6 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AMPH stock?
As of September 30, 2026, the largest Amphastar Pharmaceuticals, Inc. (AMPH) holders among the 13F filers tracked by SignalX were BlackRock ($132.1 million), Dimensional Fund Advisors ($61.5 million), State Street Corp ($43.2 million), Vanguard Capital Management LLC ($32.0 million), D.E. Shaw & Co ($29.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AMPH's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $719.9 million (down 1.7% from FY2024) and net income of $98.1 million. Diluted EPS was $2.03. The figures come from the XBRL data in the 10-K.
What did AMPH report in its latest 8-K?
Amphastar Pharmaceuticals, Inc. (AMPH) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 results announced for the three months ended September 30, 2026.
What are the latest AMPH SEC filings?
Amphastar Pharmaceuticals, Inc. (AMPH) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 18, 2026.
What is AMPH's SEC CIK number?
Amphastar Pharmaceuticals, Inc. (AMPH)'s SEC Central Index Key (CIK) is 1297184. EDGAR lists every AMPH filing under that number.
Ask anything about AMPH
The research agent reads AMPH's filings, financials, insider trades and 13F holders, then answers with sources.